Allergic Asthma

Antisense GATA-3 Abrogated Pulmonary Inflammation In Vivo

Published in Gene Therapy Weekly, August 16th, 2001

by Deborah W. Heinrich, PhD, staff medical writer - Scientists in the United States are taking a new approach to alleviating hyperresponsiveness in asthma with GATA-3 gene therapy in an animal model.

While previous research demonstrated the importance of GATA-3 in the development of asthma by preventing Th2-mediated allergic airway inflammation in transgenic mice expressing dominant negative GATA-3 in T cells, it did not clarify whether GATA-3 played an effector roll or whether it could be used as a target for gene therapy. These questions were addressed by S. Finotto and colleagues, Brigham and Women's Hospital, Boston, Massachusetts.

In their...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry